Ser330

Site Information
EDCFEsEsEDEFYKQ SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 20621672

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:	breast cancer ( 2 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 )
Relevant cell line - cell type - tissue:	293E (epithelial) ( 3 ) , breast ( 1 ) , BT-549 (breast cell) ( 2 ) , HCC1937 (breast cell) ( 2 ) , MCF-7 (breast cell) ( 2 ) , MDA-MB-231 (breast cell) ( 2 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
3	Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22 21659604 Curated Info